AI Meets Aging Research: First Epigenetic Age Reversal Drug Candidate Nears Human Trials
Harvard's David Sinclair previews ER-100, an epigenetic age reversal drug candidate heading toward human trials, alongside a new paper on using AI and eye imaging as a biomarker for health span.
Subscribe to unlock all stories
Get full access to The Singularity Ledger, archive included.
Cancel anytime. Payments powered by Stripe.